Hepatitis C SIG: Navigating the road to elimination of HCV in the U.S.
Recorded On: 11/09/2018
This program covers the key components that support efforts to define a program toward eradication of HCV in the U.S. The program is centered around modeling, engagement of individuals difficult to link to care and screening efforts. Access to care and the role of advocacy is instrumental and approaches toward successful advocacy will also be discussed.
John W. Ward
Nancy S. Reau (Moderator)
Dr. Nancy Reau is currently Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center. Dr Reau’s research interest is in viral hepatitis drug development as well as utilisation. She has authored or co-authored over 100 peer-reviewed articles, invited reviews, editorials and online programmes, as well as several book chapters, and two books. She is the editor in chief for Clinical Liver Disease, the AASLD multimedia journal. She was one of the original authors of the AASLD/IDSA hepatitis C guidance document. She is currently a member of the steering committee for the hepatitis C special interest group for the AASLD and is a member of the gastroenterology writing committee for the American Board of Internal Medicine.
Stacey Trooskin, MD PhD, is the Director of Viral Hepatitis Programs at Philadelphia FIGHT Community Health Centers and Clinical Assistant Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania. She received her MPH from Yale University School of Public Health, her medical degree from Robert Wood Johnson Medical School, and her PhD from Rutgers School of Public Health. She completed her internal medicine residency and infectious diseases fellowship at the Hospital of the University of Pennsylvania.
Dr. Trooskin’s primary research interest focuses on health disparities and developing and evaluating innovative models of HCV testing and linkage to care. Dr. Trooskin serves at the Chief Medical Advisor to the National Viral Hepatitis Roundtable and is a member of the AASLD/IDSA HCV Guidelines Committee. She is the Community Co-chair of the Hepatitis C Allies of Philadelphia (HepCAP) and the Principal Investigator of C Change: Philadelphia’s Plan to End Hepatitis C Among People Who Inject Drugs.
Robert G. Gish
Dr. Robert G. Gish is a Clinical Professor of Medicine at the University of Nevada in Las Vegas and is a senior consultant at St Joseph’s Medical Center in Phoenix as well as Professor Consultant, Stanford University. In 2013, he founded the consulting company Robert G. Gish Consultants, LLC to provide consultative support to Pharma, nonprofits and hepatology centers and liver transplant programs that wish to start or grow their programs through pathways of quality and optimal patient care that is integrated with research and education. Dr. Gish began his medical training in 1974 when he was enrolled in the pharmacy school at the University of Kansas and then transferred to the University of Kansas Medical School in 1977 and finished his Doctor of Medicine degree in 1980. Dr. Gish went on to complete a three year internal medicine residency at the University of California, San Diego and a four-year gastroenterology and hepatology fellowship at the University of California, Los Angeles. Dr. Gish has had and continues to have an active research program in viral hepatitis, liver transplant, bio-artificial liver, and public policy especially related to liver cancer, liver transplantation, and viral hepatitis.
Andrew J. Muir (Moderator)
Dr. Andrew Muir is a gastroenterologist whose research activities are focused on developing innovative treatments for a variety of liver diseases. Through his work at the Durham Veterans Administration Medical Center, Dr. Muir has participated in the development programs of many of the direct acting antiviral agents that have revolutionized hepatitis C care. He assumed the leadership of the Gastroenterology and Hepatology Research program at DCRI in 2010 and has expanded the research portfolio to include other liver disorders and gastroenterology outcomes. His particular interests include viral hepatitis, primary sclerosing cholangitis, and liver transplantation. He also has a longstanding interest in healthcare disparities.